Innovation New Jersey
  • Home
  • Our Coalition
    • Contact Us
  • News
  • Resources
    • State Supports
    • Federal Supports
    • Higher Ed Supports
  • Join Us

Innovation News

Everything Innovation. Everything New Jersey.
Follow us and stay connected.

PhRMA Publishes New Report that Celebrates ‘A Decade of Breakthroughs in Cancer’

6/6/2016

0 Comments

 
Washington, DC ― The pace of science is yielding remarkable innovation for cancer patients as we learn more about the underlying factors driving the spread and growth of cancer.
 
These advances are opening new doors for treatment across a number of cancers, and at this week’s annual meeting of the American Society of Clinical Oncology (ASCO), we expect exciting new research on how novel waves of treatments may be able to further halt the spread of deadly cancers.
 
To celebrate this progress, a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, “A Decade of Innovation in Cancer,” highlights several cancers where significant advances over the past decade have transformed the way we treat the more than 200 diseases we call cancer, driving increased survival and better quality of life.
 
Here are some highlights from the new report:
​
  • Melanoma: A wave of immunotherapies has transformed the treatment of the metastatic disease. Before 2011, the median survival for metastatic melanoma patients was less than a year – recently released data show that in one clinical trial, 40 percent of metastatic melanoma patients have survived three years after initiating immunotherapy.
 
  • Breast cancer: Personalized medicines have opened important new doors for patients with HER2-positive breast cancer, which tend to be more aggressive than other types of breast cancer. One of these promising new therapies, called antibody drug conjugates, links powerful chemotherapy agents to an antibody, helping to steer the medicine directly to the tumor. These “smart bombs” enable the precise delivery of the medicine directly to the cancer cells, resulting in tumor shrinkage and prolonged survival.
 
  • Cervical cancer: Virtually all cervical cancer is caused by the human papilloma virus (HPV), with several strains being identified as increasing that risk. Since the introduction of the first HPV vaccines, prevalence of HPV infection has dropped 64 percent among girls ages 14 to19, helping to protect against cervical cancer.
 
  • Lung cancer: Researchers have uncovered a number of genetic mutations that cause uncontrolled cancer cell growth. In advanced non-small cell lung cancer (NSCLC), several targeted therapies have emerged that interrupt those pathways, halting cancer growth. Two-thirds of advanced NSCLCs have a genetic mutation that can directly point to treatment, and more are continually being discovered.
 
As researchers continue to uncover additional important new uses for these medicines, we learn that genetic mutations driving cancer cell growth may be present among a variety of cancers.
 
Similarly, the pathways by which cancers evade our immune system are present among a variety of cancers, and we are seeing the application of immunotherapies across a number of disease areas.
 
In fact, the first immunotherapies for bladder cancer and for Hodgkin lymphoma were recently approved, and a new type of cellular immunotherapy, CAR-T, looks to take individualized immune-therapy to the next level.  CAR-T extracts a patient’s own T-cells and re-engineers them to recognize cancer cells.  When reintroduced, these “hunter” immune cells can recognize, zero in on and kill cancer cells.
 
As the burden of cancer grows in the coming years, these treatment advances, and those to come, like CAR-T therapy, will provide an important foundation for new waves of treatment options, offering patients and their loved ones a brighter outlook for the future.
 
This progress also underscores the need to maintain an ecosystem that fosters the development of tomorrow’s cancer treatments and cures.
 
Learn more about how America’s biopharmaceutical research companies are fighting cancer here.
 
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. 
 
Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.
 
To visit PhRMA’s information-packed blog, The Catalyst, click here.
 
0 Comments



Leave a Reply.

    Do not miss a single innovative moment and sign up for our newsletter!
    Weekly updates


    Categories

    All
    3D Printing
    Academia
    Acquisitions
    Aerospace
    Agriculture
    AIDS
    Algae
    Alumni
    Animals
    Architecture
    Astrophysics
    Autism
    Awards
    Big Data
    Bioethics
    Biofuel
    Biomedical
    BioNJ
    Bioterrorism
    Bit Coins
    Brain Health
    Business
    Camden
    Cancer
    CCollege
    Cellular
    Centenary
    Chemistry
    ChooseNJ
    Climate Change
    Clinical Trials
    Cloud Tech
    Collaboration
    Computing
    Congress
    Coriell
    Council On Innovation
    Crowdfunding
    Cybersecurity
    DARPA
    Defense
    Degree
    Dementia
    Dental Health
    DOC
    DOD
    DOE
    Drew
    Drones
    Drug Creation
    Einstein's Alley
    Electricity
    Energy
    Engineering
    Entrepreneurship
    Environmental
    FAA
    Fairleigh Dickinson
    FDA
    Federal Budget
    Federal Government
    Federal Labs
    Federal Program
    Finance
    Food Science
    Fort Monmouth
    Fuel Cells
    Funding
    Genome
    Geography
    Geology
    Global Competition
    Google
    Governor Christie
    Grant
    Hackensack
    HackensackUMC
    Healthcare
    Health Care
    HHS
    HINJ
    Hospitals
    Immigration
    Incubator
    Infrastructure
    International
    Internet
    Investor
    IoT
    IP
    IT
    Jobs
    Johnson & Johnson
    K-12
    Kean
    Kessler
    Legislation
    Logistics
    Manufacturing
    Medical Devices
    Med School
    Mental Health
    Mentor
    Microorganisms
    Molecular Biology
    Montclair
    NAS
    Neuroscience
    Newark
    New Jersey
    NIFA
    NIH
    NIST
    NJBDA
    NJBIA
    NJ Chemistry Council
    NJCU
    NJDOLWD
    NJEDA
    NJEDge
    NJHF
    NJII
    NJIT
    NJMEP
    NJPAC
    NJPRO
    NJTC
    Nonprofit
    NSF
    OpEd
    Open Data
    OSHE
    OSTP
    Parasite
    Patents
    Paterson
    Patients
    Perth Amboy
    Pharma
    POTUS
    PPPL
    Princeton
    Prosthetics
    Ranking
    Rare Disease
    R&D Council
    Report
    Resiliency
    Rider
    Robotics
    Rowan
    Rutgers
    SBA
    Seton Hall
    Siemens
    Smart Car
    Smart Cities
    Software
    Solar
    Space
    SSTI
    Startup
    State Government
    STEM
    Stevens
    Stockton
    Subatomic
    Supports
    Sustainability
    Taxes
    TCNJ
    Teachers
    Telecom
    Therapy
    Thermodynamics
    Transportation
    Undergraduate
    USEDA
    Verizon
    Video Game
    Virtual Reality
    Water
    WHO
    William Paterson
    Women In STEM
    Workforce Development

Home   Coalition   News   Resources   Events   Join Us
Picture
Innovation New Jersey Coalition
222 West State Street
Suite 302
Trenton, NJ 08608
732-729-9619